Ofosu F A, Lormeau J C, Craven S, Dewar L, Anvari N
Canadian Red Cross Society, Blood Services, Hamilton Centre, Ontario.
Thromb Haemost. 1994 Dec;72(6):862-8.
Factor V activation is a critical step preceding prothrombinase formation. This study determined the contributions of factor Xa and thrombin, which activate purified factor V with similar catalytic efficiency, to plasma factor V activation during coagulation. Prothrombin activation began without a lag phase after a suspension of coagulant phospholipids, CaCl2, and factor Xa was added to factor X-depleted plasma. Hirudin, a potent thrombin inhibitor, abrogated prothrombin activation initiated with 0.5 and 1.0 nM factor Xa, but not with 5 nM factor Xa. In contrast, hirudin did not abrogate prothrombin activation in plasmas pre-incubated with 0.5, 1.0 or 5 nM alpha-thrombin for 10 s followed by the coagulant suspension containing 0.5 nM factor Xa. Thus, thrombin activates plasma factor V more efficiently than factor Xa. At concentrations which doubled the clotting time of contact-activated normal plasma, heparin and three low Mr heparins also abrogated prothrombin activation initiated with 0.5 nM factor Xa, but not with 5 nM factor Xa. If factor V in the factor X-depleted plasma was activated (by pre-incubation with 10 nM alpha-thrombin for 60 s) before adding 0.5, 1.0, or 5 nM factor Xa, neither hirudin nor the heparins altered the rates of prothrombin activation. Thus, none of the five anticoagulants inactivates prothrombinase. When 5 or 10 pM relipidated r-human tissue factor and CaCl2 were added to normal plasma, heparin and the three low Mr heparins delayed the onset of prothrombin activation until the concentration of factor Xa generated exceeded 1 nM, and they subsequently inhibited prothrombin activation to the same extent.(ABSTRACT TRUNCATED AT 250 WORDS)
因子V激活是凝血酶原酶形成之前的关键步骤。本研究确定了以相似催化效率激活纯化因子V的因子Xa和凝血酶在凝血过程中对血浆因子V激活的作用。在将凝血剂磷脂、氯化钙和因子Xa的悬浮液添加到缺乏因子X的血浆后,凝血酶原激活无延迟期开始。水蛭素是一种有效的凝血酶抑制剂,它能消除由0.5和1.0 nM因子Xa引发的凝血酶原激活,但不能消除由5 nM因子Xa引发的激活。相反,水蛭素不能消除在与0.5、1.0或5 nMα-凝血酶预孵育10秒后再加入含0.5 nM因子Xa的凝血剂悬浮液的血浆中的凝血酶原激活。因此,凝血酶比因子Xa更有效地激活血浆因子V。在使接触激活的正常血浆凝血时间加倍的浓度下,肝素和三种低分子量肝素也消除了由0.5 nM因子Xa引发的凝血酶原激活,但不能消除由5 nM因子Xa引发的激活。如果在添加0.5、1.0或5 nM因子Xa之前,将缺乏因子X的血浆中的因子V激活(通过与10 nMα-凝血酶预孵育60秒),水蛭素和肝素都不会改变凝血酶原激活的速率。因此,这五种抗凝剂都不会使凝血酶原酶失活。当将5或10 pM重新脂质化的重组人组织因子和氯化钙添加到正常血浆中时,肝素和三种低分子量肝素会延迟凝血酶原激活的开始,直到产生的因子Xa浓度超过1 nM,随后它们对凝血酶原激活的抑制程度相同。(摘要截短至250字)